Current status and recommendations for biomarkers and biobanking in neurofibromatosis

C Oliver Hanemann; Jaishri O Blakeley; Fabio P Nunes; Kent Robertson; Anat Stemmer-Rachamimov; Victor Mautner; Andreas Kurtz; Michael Ferguson; Brigitte C Widemann; Gareth Evans; Rosalie Ferner; Steven L Carroll; Bruce Korf; Pierre Wolkenstein; Pamela Knight; Scott R Plotkin; REiNS International Collaboration

doi:10.1212/WNL.0000000000002932

Current status and recommendations for biomarkers and biobanking in neurofibromatosis

C Oliver Hanemann, Jaishri O Blakeley, Fabio P Nunes, Kent Robertson, Anat Stemmer-Rachamimov, Victor Mautner, Andreas Kurtz, Michael Ferguson, Brigitte C Widemann, Gareth Evans, Rosalie Ferner, Steven L Carroll, Bruce Korf, Pierre Wolkenstein, Pamela Knight, Scott R Plotkin, REiNS International Collaboration

Division of Evolution, Infection and Genomics

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).

METHODS: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings.

RESULTS: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks.

CONCLUSIONS: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.

Original language	English
Pages (from-to)	S40-48
Number of pages	9
Journal	Neurology
Volume	87
Issue number	7 Suppl 1
DOIs	https://doi.org/10.1212/WNL.0000000000002932
Publication status	Published - 16 Aug 2016

Access to Document

10.1212/WNL.0000000000002932

Cite this

Hanemann, C. O., Blakeley, J. O., Nunes, F. P., Robertson, K., Stemmer-Rachamimov, A., Mautner, V., Kurtz, A., Ferguson, M., Widemann, B. C., Evans, G., Ferner, R., Carroll, S. L., Korf, B., Wolkenstein, P., Knight, P., Plotkin, S. R., & REiNS International Collaboration (2016). Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 87(7 Suppl 1), S40-48. https://doi.org/10.1212/WNL.0000000000002932

@article{c7046288f80b4934a7b7697bea6743ad,

title = "Current status and recommendations for biomarkers and biobanking in neurofibromatosis",

abstract = "OBJECTIVE: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).METHODS: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings.RESULTS: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks.CONCLUSIONS: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.",

author = "Hanemann, {C Oliver} and Blakeley, {Jaishri O} and Nunes, {Fabio P} and Kent Robertson and Anat Stemmer-Rachamimov and Victor Mautner and Andreas Kurtz and Michael Ferguson and Widemann, {Brigitte C} and Gareth Evans and Rosalie Ferner and Carroll, {Steven L} and Bruce Korf and Pierre Wolkenstein and Pamela Knight and Plotkin, {Scott R} and {REiNS International Collaboration}",

note = "{\textcopyright} 2016 American Academy of Neurology.",

year = "2016",

month = aug,

day = "16",

doi = "10.1212/WNL.0000000000002932",

language = "English",

volume = "87",

pages = "S40--48",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams & Wilkins",

number = "7 Suppl 1",

}

Hanemann, CO, Blakeley, JO, Nunes, FP, Robertson, K, Stemmer-Rachamimov, A, Mautner, V, Kurtz, A, Ferguson, M, Widemann, BC, Evans, G, Ferner, R, Carroll, SL, Korf, B, Wolkenstein, P, Knight, P, Plotkin, SR & REiNS International Collaboration 2016, 'Current status and recommendations for biomarkers and biobanking in neurofibromatosis', Neurology, vol. 87, no. 7 Suppl 1, pp. S40-48. https://doi.org/10.1212/WNL.0000000000002932

TY - JOUR

T1 - Current status and recommendations for biomarkers and biobanking in neurofibromatosis

AU - Hanemann, C Oliver

AU - Blakeley, Jaishri O

AU - Nunes, Fabio P

AU - Robertson, Kent

AU - Stemmer-Rachamimov, Anat

AU - Mautner, Victor

AU - Kurtz, Andreas

AU - Ferguson, Michael

AU - Widemann, Brigitte C

AU - Evans, Gareth

AU - Ferner, Rosalie

AU - Carroll, Steven L

AU - Korf, Bruce

AU - Wolkenstein, Pierre

AU - Knight, Pamela

AU - Plotkin, Scott R

AU - REiNS International Collaboration

PY - 2016/8/16

Y1 - 2016/8/16

N2 - OBJECTIVE: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).METHODS: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings.RESULTS: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks.CONCLUSIONS: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.

AB - OBJECTIVE: Clinically validated biomarkers for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis (SWN) have not been identified to date. The biomarker working group's goals are to (1) define biomarker needs in NF1, NF2, and SWN; (2) summarize existing data on biomarkers in NF1, NF2, and SWN; (3) outline recommendations for sample collection and biomarker development; and (4) standardize sample collection and methodology protocols where possible to promote comparison between studies by publishing standard operating procedures (SOPs).METHODS: The biomarker group reviewed published data on biomarkers in NF1, NF2, and SWN and on biobanking efforts outside these diseases via literature search, defined the need for biomarkers in NF, and developed recommendations in a series of consensus meetings.RESULTS: We describe existing biomarkers in NF and report consensus recommendations for SOP and a minimal clinical dataset to accompany samples derived from patients with NF1, NF2, and SWN in decentralized biobanks.CONCLUSIONS: These recommendations are intended to provide clinicians and researchers with a common set of guidelines to collect and store biospecimens and for establishment of biobanks for NF1, NF2, and SWN.

U2 - 10.1212/WNL.0000000000002932

DO - 10.1212/WNL.0000000000002932

M3 - Article

C2 - 27527649

SN - 0028-3878

VL - 87

SP - S40-48

JO - Neurology

JF - Neurology

IS - 7 Suppl 1

ER -

Current status and recommendations for biomarkers and biobanking in neurofibromatosis

Abstract

Access to Document

Fingerprint

Cite this